Significant decreased expressions of CaN, VEGF, SLC39A6 and SFRP1 in MDA-MB-231 xenograft breast tumor mice treated with moringa oleifera leaves and seed residue (MOLSr) extracts

• Published in: Nutrients
• Main Author: 2-s2.0-85091767399
• Format: Article
• Language: English
• Published: MDPI AG 2020
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091767399&doi=10.3390%2fnu12102993&partnerID=40&md5=aff7531360ede1b0fca56f65e4314ee9

Moringa oleifera is a miracle plant with many nutritional and medicinal properties. Chemopreventive values of the combined mixture of moringa leaves and seed residue (MOLSr) at different ratios (M1S9, M1S1 and M9S1) were investigated. MOLSr extracts were subjected to phytochemical screening, antioxidant assays, metabolite profiling and cytotoxic activity on the primary mammary epithelial cells (PMECs), non-malignant Chang’s liver cells and various human cancer cell lines (including breast, cervical, colon and liver cancer cell lines). The MOLSr ratio with the most potent cytotoxic activity was used in xenograft mice injected with MDA-MB-231 cells for in vivo tumorigenicity study as well as further protein and gene expression studies. M1S9, specifically composed of saponin and amino acid, retained the lowest antioxidant activity but the highest glucosinolate content as compared to other ratios. Cell viability decreased significantly in MCF-7 breast cancer cells and PMECs after treatment with M1S9. Solid tumor from MDA-MB-231 xenograft mice was inhibited by up to 64.5% at third week after treatment with high-dose M1S9. High-dose M1S9 significantly decreased the expression of calcineurin (CaN) and vascular endothelial cell growth factor (VEGF) proteins as well as the secreted frizzled-related protein 1 (SFRP1) and solute carrier family 39 member 6 (SLC39A6) genes. This study provides new scientific evidence for the chemoprevention potential of MOLSr extracts in a breast cancer model; however, the precise mechanism warrants further investigation. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.